2,3-Dimethyl-imidazo<1,2-b>pyridazin | 17412-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,3-Dimethyl-imidazo<1,2-b>pyridazin
• 英文别名: 2,3-dimethyl-imidazo[1,2-b]pyridazine；Gsjcjqlkrsbuil-uhfffaoysa-；2,3-dimethylimidazo[1,2-b]pyridazine
• CAS: 17412-31-6
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: GSJCJQLKRSBUIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME
  申请人：Janssen Pharmaceutica NV

  公开号：US20150203498A1

  公开（公告）日：2015-07-23

  The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-b]吡啶嗪和咪唑并[1,2-a]-吡嗪衍生物，这些衍生物是磷酸二酯酶10酶（PDE10）的抑制剂，可能用于治疗或预防涉及PDE10酶的神经、精神和代谢紊乱。该发明还涉及含有这些化合物的药物组合物，制备这些化合物和组合物的方法，以及利用这些化合物或药物组合物预防或治疗神经、精神和代谢紊乱和疾病。
• NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS
  申请人：Blumberg Laura C.

  公开号：US20080275235A1

  公开（公告）日：2008-11-06

  Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

  本发明涉及融合的杂环化合物，包括其衍生物，以及制备它们的中间体，含有它们的制药组合物以及它们的药用用途。本发明的化合物是转化生长因子（“TGF”）信号通路的有效抑制剂。它们在治疗各种与TGF相关的疾病状态方面非常有用，包括癌症和纤维化疾病等。
• PHENOXYMETHYL HETEROCYCLIC COMPOUNDS
  申请人：ENVIVO PHAMACEUTICALS, INC.

  公开号：US20130143888A1

  公开（公告）日：2013-06-06

  Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.

  本文描述了抑制至少一种磷酸二酯酶10的苯甲氧基化合物，以及包含这些化合物的药物组合物和通过将这些化合物用于需要治疗的患者来治疗各种中枢神经系统疾病的方法。
• Phenoxymethyl heterocyclic compounds
  申请人：Envivo Pharmaceuticals, Inc.

  公开号：EP2617420A1

  公开（公告）日：2013-07-24

  A pharmaceutical composition comprising 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one which inhibits at least one phosphodiesterase 10 is described for treating various CNS disorders by administering such compounds to a patient in need thereof.

  一种药物组合物包含 4-(4-(咪唑并[1,2-b]哒嗪-2-基甲氧基)苯基)-2,2-二甲基-5-(吡啶-4-基)呋喃-3(2H)-酮，可抑制至少一种磷酸二酯酶 10。